Aditxt Inc. Subsidiary Pearsanta Advances in DoD-Funded Ovarian Cancer Diagnostic Study
TL;DR
Aditxt's subsidiary Pearsanta, Inc. could gain a competitive edge with the Mitomic Ovarian Test, potentially securing a $350,000 grant for early ovarian cancer detection innovation.
Pearsanta, Inc. plans to validate the Mitomic Ovarian Test through a multi-center clinical study, aiming for commercial launch as a laboratory-developed test with DoD funding.
The Mitomic Ovarian Test by Pearsanta, Inc. represents a leap forward in women's health, offering hope for early detection and better outcomes in ovarian cancer.
Discover how Aditxt's Pearsanta, Inc. is revolutionizing ovarian cancer detection with a novel blood-based test, backed by a potential $350,000 DoD grant.
Found this article helpful?
Share it with your network and spread the knowledge!
Aditxt Inc. (NASDAQ: ADTX), a leader in advancing health technologies through its social innovation platform, has announced a significant milestone for its subsidiary, Pearsanta, Inc. Pearsanta has been invited to submit a full proposal for the U.S. Department of Defense’s (DoD) Ovarian Cancer Research Program (OCRP) Pilot Award. This opportunity underscores the potential of Pearsanta’s Mitomic(R) Ovarian Test (MOT(TM)), a groundbreaking blood-based diagnostic designed for the early detection of ovarian cancer.
The invitation to submit a full proposal follows a favorable review of Pearsanta’s pre-proposal, which highlighted the test’s scientific merit and innovation. The DoD grant could provide up to $350,000 over two years, funding that would support a multi-center clinical study to validate the MOT(TM) and prepare for its commercial launch as a laboratory-developed test. This development represents a critical step forward in the fight against ovarian cancer, a disease that often goes undetected until its later stages due to the lack of early symptoms and effective screening methods.
The potential impact of this diagnostic tool is immense. Early detection of ovarian cancer can significantly improve treatment outcomes and survival rates. The MOT(TM) test, by leveraging cutting-edge technology to identify cancer at an early stage, could revolutionize the way ovarian cancer is diagnosed and treated. For the healthcare industry, the successful development and commercialization of this test could set a new standard in cancer diagnostics, offering a non-invasive, accurate, and early detection method that could be applied to other types of cancer in the future.
Aditxt’s commitment to advancing health technologies through its innovative platform is evident in this initiative. By fostering collaboration among research institutions, industry partners, and shareholders, Aditxt aims to accelerate the development and deployment of solutions to some of the most pressing health challenges. The progress of Pearsanta’s MOT(TM) test is a testament to the potential of this collaborative model to bring about meaningful advancements in healthcare.
For more information on Aditxt and its initiatives, visit https://www.Aditxt.com. The latest updates on Aditxt Inc. can also be found in the company’s newsroom at https://ibn.fm/ADTX.
Curated from InvestorBrandNetwork (IBN)
